Today: Today: Icon Advisers Inc. Co. Buys 1,900 Shares of Alexion Pharmaceuticals Inc. (ALXN)

Today: Icon Advisers Inc. Co. Buys 1,900 Shares of Alexion Pharmaceuticals Inc. (ALXN)

Icon Advisers Inc. Co. boosted its position in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 9.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,900 shares of the biopharmaceutical company’s stock after buying an additional 1,900 shares during the period. Icon Advisers Inc. Co.’s holdings in Alexion Pharmaceuticals were worth $2,684,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Eqis Capital Management Inc. raised its stake in Alexion Pharmaceuticals by 4.3% in the second quarter. Eqis Capital Management Inc. now owns 9,727 shares of the biopharmaceutical company’s stock worth $1,136,000 after buying an additional 400 shares during the last quarter. MAI Capital Management raised its stake in Alexion Pharmaceuticals by 46.5% in the second quarter. MAI Capital Management now owns 4,281 shares of the biopharmaceutical company’s stock worth $500,000 after buying an additional 1,358 shares during the last quarter. Capstone Asset Management Co. raised its stake in Alexion Pharmaceuticals by 4.7% in the second quarter. Capstone Asset Management Co. now owns 24,573 shares of the biopharmaceutical company’s stock worth $2,869,000 after buying an additional 1,095 shares during the last quarter. Gateway Investment Advisers LLC raised its stake in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock worth $21,582,000 after buying an additional 23,032 shares during the last quarter. Finally, Webster Bank N. A. raised its stake in Alexion Pharmaceuticals by 40.0% in the second quarter. Webster Bank N. A. now owns 7,000 shares of the biopharmaceutical company’s stock worth $817,000 after buying an additional 2,000 shares during the last quarter. Hedge funds and other institutional investors own 94.85% of the company’s stock.

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 0.1866% during mid-day trading on Monday, reaching $118.6083. The company had a trading volume of 529,968 shares. The stock’s 50-day moving average is $122.72 and its 200 day moving average is $129.05. Alexion Pharmaceuticals Inc. has a 12 month low of $110.56 and a 12 month high of $193.45. The firm has a market capitalization of $26.59 billion, a P/E ratio of 72.3221 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.19. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The company earned $799 million during the quarter, compared to analysts’ expectations of $787.07 million. During the same quarter in the prior year, the business posted $1.16 earnings per share. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current fiscal year.

Several brokerages have commented on ALXN. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price target on the stock. in a research note on Wednesday, August 3rd. Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 9th. Piper Jaffray Cos. reiterated an “overweight” rating and issued a $185.00 price target on shares of Alexion Pharmaceuticals in a research note on Tuesday, August 16th. Wedbush began coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, September 22nd. They issued a “neutral” rating and a $132.00 price target on the stock. Finally, Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $173.36.

In other news, EVP Carsten Thiel sold 1,000 shares of the company’s stock in a transaction on Tuesday, September 6th. The stock was sold at an average price of $125.94, for a total value of $125,940.00. Following the completion of the sale, the executive vice president now owns 40,579 shares in the company, valued at $5,110,519.26. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Leonard Bell sold 37,317 shares of the company’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $140.38, for a total value of $5,238,560.46. Following the completion of the sale, the director now owns 440,936 shares of the company’s stock, valued at approximately $61,898,595.68. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.

Alexion Pharmaceuticals Company Profile

Related posts

Leave a Comment